title: Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role?
authors.affiliation: Department of Cutaneous Oncology, 12902 Magnolia Drive, Tampa, Florida 33612, USA. vernon.sondak@moffitt.org
authors.forename: Vernon K
authors.initials: VK
authors.lastname: Sondak
authors.forename: Ragini
authors.initials: R
authors.lastname: Kudchadkar
mesh_terms: D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b